$69 non-ATF Mobile

NeuroScientific (ASX:NSB) initiates preclinical study to evaluate treatment for Post-COVID Fibrosis

  • November 20, 2020 04:07 PM AEDT
  • Team Kalkine
NeuroScientific (ASX:NSB) initiates preclinical study to evaluate treatment for Post-COVID Fibrosis

Summary

  • Neuroscientific Biopharmaceuticals is collaborating with The Institute of Respiratory Health and The University of Western Australia to evaluate the efficacy of EmtinB and other compounds as a potential treatment for post-COVID fibrosis.
  • NSB would provide A$122,000 to the Institute of Respiratory Health for commencing the screening stage. The preliminary data would be available in 1H 2021.
Gold MTF non-AMP

Neuroscientific Biopharmaceuticals Limited (ASX:NSB), in partnership with The Institute of Respiratory Health and The University of Western Australia, has initiated a new preclinical program to study the effects of EmtinB and other compounds (developed from metallothionein-II) as a potential treatment for patients suffering 'post-COVID fibrosis'.

The Nedlands-headquartered pharmaceutical company specialises in the development of peptide-based pharmaceutical drugs that aim to address several neurodegenerative conditions with high unmet need.

Preclinical Program Collaboration

Through this partnership, the concerned parties would assess the efficacy of EmtinB and other metallothionein-derived peptides as a possible treatment for long term respiratory complications of Covid-19.

The Molecular Pathology Research Unit would run the preclinical program at the Institute of Respiratory Health and UWA with the help of NeuroScientific's peptide-based compounds. In this process, the Company would provide A$122,000 to the Institute of Respiratory Health for commencing the screening stage with the initial term of the research agreement agreed at four months.

The preliminary data from this new program would be available in 1H 2021.

Since its discovery in December 2019, SARS-CoV-2 has been spreading at an alarming rate with nearly 56 million cases as per the WHO (as on 19 November). With the continuous surge, it is possible that post-COVID-19 fibrosis would become one of the biggest burdens on global healthcare in the future.

Post-COVID fibrosis is irreversible and could have severe functional limitations like severe cough, shortness of breath, need for oxygen and lung transplants in a few situations. As per the latest data, pulmonary fibrosis due to COVID-19 is increasing in number with patients in the age group 20-40. The disease, as a result, is likely to create a severe global healthcare burden in the future.

A COVID-19 patient who develop Acute Respiratory Distress Syndrome (ARDS) can endure the acute phase of the illness. However, there are chances that the person might die because of progressive pulmonary fibrosis. Post-COVID fibrosis could cause long-lasting damage to the lungs, even in young adult patients.

According to recent data from independent research organisation, a natural form of EmtinB, metallothionein can protect the lungs from such injury and fibrosis.

A Glance at the Astonishing Statistics:

According to the available data, ~40% of COVID-19 patients develop ARDS, with 20% of ARDS cases falling in the severe category. Early assessment from COVID-19 patients on hospital discharge shows that over 33% of the recovered patients develop fibrotic abnormalities. Further, 47% of the patients have impaired diffusing capacity of the lungs for carbon monoxide, and 25% have reduced lungs capacity.

Stock Information: At AEDT 3:49 PM, NSB shares were trading at A$0.335, down 1.471%.

 

With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.

CLICK HERE FOR YOUR FREE REPORT!

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK